Popular GLP-1 weight-loss drugs linked to lower risks of addiction and overdose

Glucagon-like peptide-1 (GLP-1) receptor agonists, the drug class that includes popular weight-loss treatments such as semaglutide and tirzepatide, have been inversely linked with hospital visits for opioid use disorder and overdose. The large-scale analysis outlined by Science Daily, coordinated by Vanderbilt University, draws on records for 1.3 million patients.

The study searched the US multi-institution electronic health records consortium N3C. Researchers classified obesity-diagnosed patients aged 18-75 into those starting semaglutide or tirzepatide and a matched control group; follow-up ran for 24 months.

The data showed GLP-1 users had 33% fewer emergency department visits with a diagnosis of opioid use disorder and 29% fewer hospital admissions for overdose. Alcohol use disorder showed a trend toward an 18% reduction.

Lead author Dr Patricia Watson, of Vanderbilt University Medical Center, told Science Daily: "This is a strong observational signal. It is consistent with findings from animal models showing GLP-1s act on the reward circuit."

On mechanism, GLP-1 receptors are known to be present in brain regions such as the ventral tegmental area and nucleus accumbens, where they can dampen dopamine signalling. This hypothetical mechanism has produced mild positive signals in small human trials of smoking cessation as well.

Clinicians read the data cautiously. Dr Lisa Shapiro, of Kaiser Permanente, who was not affiliated with the work, told Science Daily: "This is not a randomised trial. Patients already differ in socio-economic and healthcare-access profiles. We don't yet know whether the effect is causal or whether it reflects selection."

The US Substance Abuse and Mental Health Services Administration (SAMHSA) announced a randomised phase-3 trial of GLP-1s in opioid use disorder for later this year. The study, coordinated by the National Institute on Drug Abuse, is targeting 1,000 patients.

Drug pricing is the other side of the picture. Monthly semaglutide costs are around $1,000 in the United States. Bringing prescription access for an addiction indication into insurance coverage raises an additional policy question; Medicare currently does not cover weight-loss indications.

Side effects of the GLP-1 class can include nausea, slowed gastric emptying and rare cases of pancreatitis. The new data may require clinicians to rebalance the risk-benefit calculation in some scenarios.

This article is not medical advice. Patients receiving opioid use disorder treatment should talk with their physicians individually and remember that evidence-based therapies such as buprenorphine and methadone remain the priority.